Executive Summary
When you search “best biotechnology & gene therapy therapeutics company” on ChatGPT, Google Gemini (AI mode), or Perplexity, you keep seeing the same group of companies. You’ll notice brands like:
- CRISPR Therapeutics
- Intellia Therapeutics
- Eli Lilly (often connected to Verve Therapeutics)
- Taysha Gene Therapies
- Krystal Biotech
- Novartis / Novartis Gene Therapies
- Plus frequent mentions of Vertex, BioMarin, Beam, and Sarepta.
These companies stand out for a few main reasons:
- Clear, consistent naming and identity across their sites and third-party sources.
- Frequent citations by authoritative financial, industry, and regulatory sites like the FDA, Reuters, and sector reports.
- Pipeline news and updates align with what users seek when asking “who’s best?”
- Websites present structured, evidence-backed information on products and pipelines.
- Repeated presence in top company and investor lists, forming a “consensus” for AI models.
This report shows you why these leaders appear in AI answers, how often each gets cited, and what you can do if you want to show up in the same spaces.
Methodology
What people asked:
“What’s the best biotechnology & gene therapy therapeutics company?”
Engines checked:
- ChatGPT (“Reference 1”)
- Google Gemini AI Mode (“Reference 2”)
- Perplexity AI (“Reference 3”)
Timing: All results are from around 2026‑05‑11.
How we judged each brand:
- Frequency—How many AI engines mention it?
- Role/Label—Are they called the biggest, most innovative, or main commercial player?
- Type and number of references—How many external sources back up the claims?
- How tightly are they linked to gene therapy/gene editing specifically?
- Are AIs citing up-to-date info?
Limits:
You won’t find full, live answers in this report—just structured data and key parts of AI responses. Sometimes it’s hard to split out which citation supports which brand.
Overall Rankings Table
This table covers the most visible “top” gene therapy and gene editing companies in the eyes of three major AIs (ChatGPT, Gemini, and Perplexity).
| Rank | Company / Brand | Engines | AI Label / Role | Score | Key Source Types |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics | C, G, P | Commercial giant, approval leader, innovator | 5 | Company site, rankings, industry pipelines ([1][2][3][8][9][11][12]) |
| 2 | Intellia Therapeutics | C, G, P | Innovation leader, in-vivo CRISPR | 4.5 | Comparisons, pipelines, market cap ([1][2][3][5][11][16][17]) |
| 3 | Krystal Biotech | P | Largest pure-play, market cap leader | 4 | Market-cap, rankings ([3][4][5][11][12][15]) |
| 4 | Novartis / Novartis Gene Therapies | G, P | Marketed gene therapy, Zolgensma owner | 4 | FDA approvals, sales articles ([2][3][6][7]) |
| 5 | Eli Lilly (with Verve Therapeutics) | G | Big acquirer, focusing on gene editing | 3.5 | Market cap, deal reports ([2][11][12][17]) |
| 6 | Taysha Gene Therapies | G | Rett syndrome specialist, emerging player | 3.5 | Pipeline, “to watch” lists ([2][11][13][17]) |
| 7 | Vertex Pharmaceuticals | C, G | Casgevy partner, CF/gene editing | 3 | Earnings, market analysis ([1][2][12]) |
| 8 | BioMarin Pharmaceutical | C | Rare disease, gene therapy | 2.5 | Market cap, roundup lists ([1][4][5][11]) |
| 9 | Beam Therapeutics | C, P | Base editing innovation | 2.5 | Innovation lists, “top” articles ([1][5][11][17]) |
| 10 | Sarepta Therapeutics | C | DMD/rare disease focus | 2 | News, pipelines, “leaders” ([1][12][17]) |
C = ChatGPT [1], G = Gemini [2], P = Perplexity [3]
Note: Some other companies (Jaguar, Regenxbio, Bluebird, Genetix, etc.) show up in citations but the AIs usually do not call them “best.” They get discussed later as challengers.
Company-by-Company Breakdown
CRISPR Therapeutics (Rank #1)
- Lead in CRISPR-based gene editing therapies, both ex vivo and moving into in vivo.
- Show up in top lists for gene therapy companies ([4]), tech comparisons ([2][1]), and best CRISPR stocks ([6][8][11][17]).
- Get labeled as “commercial giant” by Gemini, anchored by Casgevy—the first FDA-approved CRISPR therapy.
- Own a clear brand and ticker (CRSP), with a tight link to gene editing.
- Maintain an up-to-date company website with clear pipeline and investor info ([9]).
- Cited in recent news, industry rankings, and pipeline tables.
Gaps: Their site speaks mainly to investors, not patients or decision-makers. For disease-specific visibility, more patient-focused content is needed.
Intellia Therapeutics (Rank #2)
- Focus on in vivo CRISPR editing, especially targeting the liver (e.g., ATTR amyloidosis).
- Grouped with CRISPR and Beam as innovation leaders; called the “Innovation Leader” by Gemini for its in vivo platform and ATTR trial data.
- Frequent mention in “companies to watch,” comparison posts, and pipeline outlooks ([2][5][11][17]).
- A clear brand, but less eponymous than CRISPR.
- Modern, AI-friendly pipeline web pages.
Gaps: Add more detailed, public disease and therapy info for dominance in disease-targeted queries.
Krystal Biotech (Rank #3)
- Focuses on gene therapy for skin diseases; Perplexity calls it “best pure-play gene therapy company.”
- Consistently tops market-cap lists ([4]) and is featured in roundups ([5][11][17]).
- Recent therapy approvals keep them in the news.
- Web design prioritizes investors but could enhance patient/outcome information.
Novartis / Novartis Gene Therapies (Rank #4)
- Major pharma with focus on gene therapy via Zolgensma.
- Included by Gemini for rare diseases and approved therapies; cited by Perplexity for FDA-approved, commercial therapies.
- Strong regulatory authority (e.g., [6][7]), but AI sometimes confuses business units.
Eli Lilly (with Verve Therapeutics) (Rank #5)
- Lilly expanded into gene therapy by acquiring Verve Therapeutics.
- Labeled “The Powerhouse Acquirer” by Gemini; noted by Perplexity for licensing deals but less as a pure gene therapy leader.
- Clear brand, but more web focus needed on gene therapy and structured visuals post-acquisitions.
Taysha Gene Therapies (Rank #6)
- Specializes in CNS gene therapy, focusing on Rett Syndrome (TSHA-102).
- Described as an emerging specialist by Gemini and included in “companies to watch” by Perplexity ([11][13][17]).
- Recent news and catalysts fuel visibility.
- Could enhance visibility by adding patient resources and clear clinical trial info, optimized for AI.
Vertex Pharmaceuticals (Rank #7)
- Focuses on cystic fibrosis; partnered with CRISPR for Casgevy.
- Mentioned by ChatGPT and Gemini as a top earner and Casgevy co-developer.
- Site provides clear company and pipeline info; visible in financial and gene editing contexts, but less as a gene therapy specialist.
BioMarin, Beam, Sarepta (Ranks #8–10)
- BioMarin appears in rare disease/gene therapy lists and market cap data ([4][5][11]).
- Beam is noted for gene editing innovation by Perplexity ([3][5][11][17]).
- Sarepta gets cited for muscular dystrophy and rare disease therapies.
- All three succeed with clear brands and “leader” designations but should add more patient-facing, structured data.
Why These Companies Stay Visible
- Clarity: Unique names/tickers on all platforms, pages, and lists—e.g., “Company Name (NASDAQ: SYMBOL)” everywhere.
- Structured data: Product pages, trial phases, and therapy info are clear and machine-readable.
- Strong citations: Frequent appearances in authoritative, independent sources (FDA, Reuters, best-of lists).
- Recent updates: Regular announcements of approvals, data, partnerships to signal leadership.
- Clear story: Each brand claims a “slot” (commercial giant, innovator, etc.) everywhere it appears.
Recommendations: How You Can Improve Your AEO Visibility
- Clarify your name: Use the same official name and ticker everywhere, from homepage to directories.
- Give each therapy a focused web page: Include indication, type, trial status, and regulatory news.
- Use structured data: Markup products, trials, and diseases with schema.org, linking therapies to conditions.
- Get cited in rankings and lists: Target inclusion in “top gene therapy companies,” etc., supplying accurate summaries.
- Keep updates fresh: Maintain a dated, public pipeline tracker and news on every milestone.
- Choose your “slot”: Brand your company (e.g., “leading in vivo CNS gene therapy”) and repeat everywhere, including structured summaries.
- Help AIs map therapies to diseases: Build pages/FAQs that answer “Who makes [therapy]?”, “What does it treat?”, with structured formats and plain language.
How AIs Used Source References
- Reuters [1]: Real-world revenues and stats for companies like Vertex.
- GeneEditing101 [2]: Comparison of CRISPR and Intellia; basis for “innovator”/”leader” labels.
- CompaniesMarketCap [4]: Market cap leaderboards for “pure plays.”
- FDA Approved Gene Therapy [6]: Authoritative list of product approvals.
- U.S. News Money [6]: Curated top CRISPR/gene editing stocks for investors.
- Labiotech [5]: “Top gene therapy companies” with narrative context.
- Cure. / WeWillCure [11]: “Companies to watch,” established leaders (2026).
- GenEngNews [7]: Best-selling therapies—Novartis/Zolgensma links.
- Vision Life Sciences [12]: Tracks licensing and partnerships (e.g., Lilly/Verve).
- Drug Discovery Trends [17]: Tracks up-and-coming gene therapy brands.
- Capital.com & Statista [15]: Market cap confirmation.
- Original company sites [9]: Pipeline and official positioning.
References
- Reuters – Vertex tops profit estimates as sales of new cystic fibrosis drug surge (2026‑05‑04)
https://www.reuters.com/legal/litigation/vertex-tops-profit-estimates-sales-new-cystic-fibrosis-drug-surge-2026-05-04/ - GeneEditing101 – Compare: CRISPR Therapeutics vs Intellia
https://geneediting101.com/compare/crispr-therapeutics-vs-intellia - CompaniesMarketCap – Largest gene therapy companies by market cap
https://companiesmarketcap.com/gene-therapy/largest-gene-therapy-companies-by-market-cap/ - FDA – Approved Cellular and Gene Therapy Products
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products - Labiotech – 10 gene therapy companies you should know about
https://www.labiotech.eu/best-biotech/gene-therapy-companies/ - U.S. News Money – 7 Top Gene-Editing Stocks to Buy
https://money.usnews.com/investing/articles/best-crispr-stocks-to-buy - Genetic Engineering & Biotechnology News – Top 10 Best-Selling Gene Therapies
https://www.genengnews.com/topics/genome-editing/top-10-best-selling-gene-therapies/ - Genemod – Top 10 Biotech Companies Advancing Gene Therapy in the US in 2026
https://genemod.net/blog/top-10-biotech-companies-advancing-gene-therapy-in-the-us-in-2026 - CRISPR Therapeutics – Official Company Site
https://crisprtx.com/ - Jaguar Gene Therapy – Company Site
https://jaguargenetherapy.com/ - Cure. / WeWillCure – 13 Cell and Gene Therapy Companies to Watch in 2026
https://wewillcure.com/insights/company-profiles/cell-and-gene-therapeutics/cell-and-gene-therapy-companies-to-watch-in-2026 - Vision Life Sciences – Gene Therapy Market 2026 | Pipeline & Licensing Deals
https://visionlifesciences.com/insights/gene-therapy-market-licensing-deals - Prime Therapeutics – Cell & Gene Pipeline Outlook: January 2026
https://www.primetherapeutics.com/cell-gene-pipeline-outlook-january-2026 - Capital.com – Largest Biotech Companies by Market Cap 2026
https://capital.com/en-int/markets/shares/largest-biotech-companies-by-market-cap - Statista – Market cap: gene and cell therapy companies 2026
https://www.statista.com/statistics/827652/gene-and-cell-therapy-companies-market-cap/ - CGTLive – Around the Helix: Cell and Gene Therapy Company Updates
https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-april-15-2026 - Drug Discovery & Development – 50 cell and gene therapy leaders to watch in 2026
https://www.drugdiscoverytrends.com/50-cell-and-gene-therapy-leaders-to-watch-in-2026/